• #LGM Pharma is a Brivaracetam CAS# 357336-20-0 API supplier distributor based in the USA. Inquire about DMF, cGMP, price, availability, delivery, purity, and more.
  • #Questions? Call our customer API support number 1-(800)-881-8210.
  • #LGM Pharma offers this active ingredient but not the finished dosage forms.

Product Details:

  • CAS No: 357336-20-0
  • AHFC code:
  • Synonyms: (2S)-2-((4R)-2-Oxo-4-propylpyrrolidin-1-yl)butanamide, Brivaracetam, UCB 34714, UCB34714, UNII-U863JGG2IA
  • ATC Code:
  • Chemical Formula: C11-H20-N2-O2
  • Molecular Weight: 212.291
  • Assay/Purity: Typically NLT 98%
  • DrugBank:
  • SMILES: CCC[C,,H]1CC(=O)[N,,](C1)C(CC)C(=O)N
  • InChl: 1S/C11H20N2O2/c1-3-5-8-6-10(14)13(7-8)9(4-2)11(12)15/h8-9H,3-7H2,1-2H3,(H2,12,15)/t8-,9?/m1/s1
  • PubChem: 9837243
  • IUPAC: 1-Pyrrolidineacetamide, alpha-ethyl-2-oxo-4-propyl-, (alphaS,4R)-

Additional Details

Indication:
Brivaracetam is indicated for adults and children ages one month and older as therapy for epilepsy, specifically partial-onset seizures.
Pharmacodynamics:
Brivaracetam is chemically related to the AED Levetiracetam and possesses a natural binding affinity for the 2A synaptic vesicle protein. A higher potency in suppressing epileptiform responses in vitro, roughly ten-fold above that of Levetiracetam, has been shown in comprehensive studies of Brivaracetam. The ability of Brivaracetam to suppress various seizure types in studies, including genetic forms of epilepsy in patients offers patients a novel inhibitory therapy.
Mode of Action:
Clearance of Brivaracetam may be reduced in patients with hepatic insufficiency, however the photo paroxysmal response model in patients diagnosed with photosensitive epilepsy has proven to be effective.
Metabolism:
Brivaracetam has a half-life of eight hours and virtually complete bioavailability. As Brivaracetam is mainly metabolized via hydrolysis of the acetamide group, as well as CYP2C8-mediated hydroxylation, its metabolites are not pharmacologically active.
Toxicity:
Brivaracetam has been tested in a comprehensive trials for toxicology, safety and genotoxicity. A low acute toxicity has been found in patients who received therapy with Brivaracetam. Commonly reported adverse effects have been documented as mild, and include fatigue, dizziness, headache and somnolence.
General Reference:
von Rosenstiel P. Brivaracetam (UCB 34714). Neurotherapeutics. 2007 Jan;4(1):84-7.Br J Pharmacol. 2008 Aug; 154(8): 1555–1557.Alzheimers Res Ther. 2015 May 5;7(1):25. doi: 10.1186/s13195-015-0110-9. eCollection 2015.Ryvlin, P., et al., Adjunctive brivaracetam in adults with uncontrolled focal epilepsy: results from a double-blind, randomized, placebo-controlled trial. Epilepsia, 2014. 55(1):47-56.
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

API’s From Quality Manufacturers:

  • Cost effective materials based on specific requirements
  • Small quantities for initial research and larger development quantities towards product commercialization

 

  • Technical packages, letters of access to filed DMFs
  • Complete assistance in any regulatory filings
  • Top quality GMP certified manufacturers
  • Have necessary regulatory credentials